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Murine fecal microbiota 
transplantation lowers 
gastrointestinal pathogen 
loads and dampens pro-
inflammatory immune responses 
in Campylobacter jejuni infected 
secondary abiotic mice
Markus M. Heimesaat*, Katharina Mrazek & Stefan Bereswill
conventional mice are protected from Campylobacter jejuni infection by the murine host-specific gut 
microbiota composition. We here addressed whether peroral fecal microbiota transplantation (fMt) 
might be an antibiotics-independent option to lower even high gastrointestinal C. jejuni loads in the 
infected vertebrate host. To address this, secondary abiotic mice were generated by broad-spectrum 
antibiotic treatment and perorally infected with C. jejuni by gavage. One week later, mice were stably 
colonized with more than 109 C. jejuni and subjected to peroral fMt from murine donors on three 
consecutive days. Two weeks post-intervention, gastrointestinal C. jejuni loads were up to 7.5 orders 
of magnitude lower following murine FMT versus mock challenge. Remarkably, FMT reversed C. jejuni 
induced colonic epithelial apoptosis, but enhanced proliferative and regenerative responses in the 
colon thereby counteracting pathogenic cell damage. Furthermore, FMT dampened both, innate and 
adaptive immune cell responses in the large intestines upon C. jejuni infection that were accompanied 
by less C. jejuni-induced colonic nitric oxide secretion. Our study provides strong evidence that novel 
probiotic formulations developed as alternative option to FMT in severe intestinal inflammatory 
morbidities including Clostridoides difficile infection might be effective to treat campylobacteriosis and 
lower pathogen loads in colonized vertebrates including farm animals.
Campylobacter jejuni constitute the most common agents of bacterial gastroenteritis in industrialized nations, 
causing more than 240,000 cases in the European Union per year1. According to the European Food Safety 
Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC), campylobacteriosis 
represents the most reported zoonosis in the European Union, by far outnumbering salmonellosis, yersinosis 
and diseases caused by pathogenic variants of Escherichia coli2. The Gram-negative bacteria are transmitted to 
humans via contaminated food products including meat, milk and eggs from livestock animals, particularly poul-
try, or surface water. Up to 40% of fresh broiler and turkey meat have been tested positive for Campylobacter 
species recently2. Whereas C. jejuni is equipped with a multi-facetted arsenal of virulence factors, humans can 
be infected with an infectious dose of 500 to 800 bacterial cells only, regardless of their health conditions3–5. 
Following predominant colonization of the terminal ileum and colon, the pathogen invades colonic epithelial 
cells and induces mucosal pro-inflammatory immune responses leading to crypt abscesses and focal ulcera-
tions6–8. After an incubation period of 2 to 5 days, infected patients present with a broad variety of symptoms 
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ranging from only mild malaise to fever, abdominal cramps, myalgia, and watery or even bloody diarrhea7–9. 
In rare cases, however, post-infectious sequelae such as Guillain-Barré syndrome, Bickerstaff encephalitis, 
Miller Fisher syndrome, Reiter’s syndrome and chronic intestinal inflammatory morbidities might arise with 
a latency of weeks to months10,11. Whereas the majority of infections is self-limited and require symptomatic 
treatment such as fluid replacement only, particularly infected multi-morbid patients with immune-suppressive 
comorbidities are subjected to antibiotic treatment. This intervention, however, is paid by expense of the poten-
tial antibiotics-induced collateral damages leading to a compromised commensal gut microbiota composition 
subsequently facilitating (opportunistic) pathogenic colonization and infection of the gastrointestinal tract, for 
instance12–15 besides to unwanted effects to the vertebrate immune system16. It is thus utmost appreciable to search 
for antibiotics-independent approaches for the prevention and treatment of C. jejuni colonization and infection 
in farm animals and humans, respectively.
In this context, one needs to take into consideration that it is the host-specific composition of the commen-
sal gut microbiota determining whether the vertebrate host is susceptible towards or resistant against C. jejuni 
infection. Conventionally colonized wildtype mice, for instance, are protected from stable C. jejuni colonization 
and infection even upon peroral infection with high pathogenic doses17–19. Following murine microbiota deple-
tion and hence, abrogation of the physiological colonization resistance by broad-spectrum antibiotic treatment, 
however, secondary abiotic mice, but also secondary abiotic mice that had been reconstituted with a complex 
human as opposed to a murine gut microbiota following fecal microbiota transplantation (FMT) could be stably 
colonized with the pathogen at high loads, but did not develop overt pathogen-induced symptoms such as wast-
ing or bloody diarrhea17.
Therapeutic application of FMT has been already reported since the fourth century during the Chinese 
Dong-jin dynasty20. Lately, FMT has experienced a renaissance as a promising treatment option of recurrent and 
refractory Clostridoides difficile toxin mediated pseudomembranous colitis in antibiotics-pretreated patients, of 
inflammatory bowel morbidities such as ulcerative colitis, irritable bowel syndrome and constipation, of obesity 
and diabetes and of chronic fatigue syndrome21–25.
Based upon these intriguing results in mice and men, we addressed in the present antibiotic-independent 
intervention/treatment study whether murine FMT in secondary abiotic mice that were harboring the pathogen 
in their gastrointestinal tract (GIT) at high loads could i.) sufficiently lower pathogenic burdens, ii.) alleviate gut 
epithelial cell damage and iii.) dampen intestinal pro-inflammatory immune responses upon C. jejuni infec-
tion. Our preclinical intervention study provides strong evidence that FMT from distinct donors might represent 
promising options for the prevention and/or treatment of C. jejuni colonization and/or infections in farm animals 
and/or humans, respectively.
Results
Gastrointestinal pathogen burdens following murine fecal microbiota transplantation in C. 
jejuni infected secondary abiotic mice. Secondary abiotic mice were perorally infected with 109 viable 
C. jejuni strain 81–176 by gavage on days 0 and 1 and harbored median loads of approximately 109 colony forming 
units (CFU) of the pathogen per g feces in both, the FMT and mock intervention cohorts a week later. On days 7, 
8 and 9 post-infection (p.i.), mice were either subjected to murine FMT or received vehicle (D0, D1, D2). Cultural 
analyses of fecal samples revealed that as early as 24 hours after the latest murine FMT (i.e., 10 days post-infec-
tion), fecal C. jejuni loads were significantly lower in the FMT versus the mock cohort (p < 0.01; Fig. 1). Until the 
end of the observation period (i.e., two weeks after the initial FMT; 21 days post-infection), median intestinal 
pathogenic burdens had decreased by up to 5 log orders of magnitude following murine FMT (p < 0.001, Fig. 1; 
Supplementary Information), but remained stable in mock control mice (n.s.; Supplementary Information). Of 
note, 12.5% of mice from the FMT cohort, but none of the mock controls had completely cleared the pathogen 
from their intestines (Supplementary Information).
Upon necropsy (i.e., 21 days post-infection, 14 days post-FMT), we assessed C. jejuni loads alongside the 
GIT. Following murine FMT, C. jejuni counts were lower in luminal samples taken from stomach, duodenum, 
ileum, and colon as compared to mock control mice (p < 0.001; Fig. 2). Our culture-independent analyses further 
confirmed that the murine microbiota had sufficiently established in the large intestines of mice following FMT 
given that gene numbers of the main bacterial species and groups abundant in the murine gut microbiota includ-
ing enterobacteria, enterococci, lactobacilli, bifidobacteria, Bacteroides/Prevotella species, Clostridium coccoides 
group, Clostridium leptum group, and Mouse Intestinal Bacteroides were comparable in the murine fecal donor 
transplants and in the gut microbiota following murine FMT (Fig. 3; Supplementary Information).
Thus, FMT could sufficiently lower gastrointestinal pathogenic loads in C. jejuni infected mice, even upon 
high-dose infection.
Apoptotic and proliferating colonic epithelial cell responses following murine fecal microbiota 
transplantation in C. jejuni infected secondary abiotic mice. In order to address whether murine 
FMT resulted in less distinct C. jejuni induced intestinal cell damage, we quantitatively assessed cleaved caspase3+ 
apoptotic cells in colonic paraffin sections applying in situ immunohistochemistry. Whereas within 21 days C. 
jejuni had induced marked increases in apoptotic colonic epithelial cell numbers in mock control mice (p < 0.005; 
Fig. 4A; Supplementary Information), this was not the case following murine FMT (p < 0.005 vs mock; Fig. 4A; 
Supplementary Information). We further quantitated Ki67+ colonic epithelial cells indicative for cell prolifera-
tion and regeneration. Whereas Ki67+ colonic epithelial cells decreased upon C. jejuni infection of mock control 
animals (p < 0.005) proliferating cell numbers were even higher in infected mice of the FMT cohort as compared 
to uninfected and untreated (i.e., naive) mice (p < 0.05; Fig. 4B; Supplementary Information). Thus, murine FMT 
prevented from C. jejuni induced colonic epithelial apoptosis and enhanced proliferative and regenerative cell 
responses in the large intestines counteracting pathogenic cell damage.
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Large intestinal inflammatory immune responses upon murine fecal microbiota transplanta-
tion of C. jejuni infected mice. We next surveyed innate and adaptive immune cell responses in the large 
intestines of C. jejuni infected mice following FMT applying quantitative in situ immunohistochemistry. At day 21 
p.i., mice displayed multi-fold increased numbers of innate immune cell subsets such as F4/80+ macrophages and 
monocytes in their colonic mucosa and lamina propria (p < 0.01–0.001 vs naive), but far less distinctly in mice of 
the FMT cohort (p < 0.001 vs mock; Fig. 5A; Supplementary Information). Furthermore, adaptive immune cell 
populations such as CD3+ lymphocytes and B220+ B lymphocytes had increased within 21 days post-infection 
of mock (p < 0.005 and p < 0.001 vs naive, respectively), but not FMT treated mice (n.s. vs naive; p < 0.005–0.001 
vs mock; Fig. 5B,D; Supplementary Information). As for F4/80+ cells, C. jejuni induced increases in FOXP3+ 
regulatory T cell numbers were less pronounced in the colonic mucosa and lamina propria following FMT versus 
mock challenge at day 21 p.i. (p < 0.005; Fig. 5C; Supplementary Information).
We further addressed whether less distinct colonic immune cell responses upon FMT of C. jejuni infected mice 
were accompanied with less intestinal pro-inflammatory mediator secretion. In fact, nitric oxide concentrations 
Figure 1. Intestinal pathogenic burdens over time following murine fecal microbiota transplantation of C. 
jejuni infected secondary abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 1 by 
gavage. Starting a week later, infected mice were subjected to peroral fecal microbiota transplantation (FMT; 
Day (D) 0) from murine donors (open circles) on three consecutive days or received vehicle (mock; closed 
circles). Before and after FMT, C. jejuni loads were determined in fecal samples taken at indicated time points 
by culture and expressed as colony forming units per gram (CFU/g). Medians, numbers of culture-positive 
mice out of the total numbers of analyzed animals (in parentheses) and significance levels (p-values; **p < 0.01; 
***p < 0.001) determined by the Mann-Whitney U test are given. Data were pooled from three independent 
experiments.
Figure 2. Gastrointestinal pathogenic loads following murine fecal microbiota transplantation of C. jejuni 
infected secondary abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 1 by gavage. 
Starting a week later, infected mice were subjected to peroral fecal microbiota transplantation (FMT) from 
murine donors (open circles) on three consecutive days or received vehicle (mock; closed circles). On day 
21 post-infection (i.e., 14 days post FMT), C. jejuni loads were determined in luminal samples taken from 
stomach, duodenum, ileum, and colon by culture and expressed as colony forming units per gram (CFU/g). 
Medians, numbers of pathogen-positive mice out of the total number of analyzed animals (in parentheses) and 
significance levels (p-values) determined by the Mann-Whitney U test are given. Data were pooled from three 
independent experiments.
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were elevated in colonic ex vivo biopsies taken from mock control animals (p < 0.001 vs naive), but not from mice 
of the FMT cohort at day 21 p.i. (p < 0.001 vs mock; Fig. 6).
Thus, murine FMT could dampen both, innate and adaptive immune responses in the large intestines upon 
C. jejuni infection that was accompanied by less C. jejuni induced colonic nitric oxide secretion. Furthermore, 
murine FMT promoted Ki67 positive cell regenerative properties also in the colon of C. jejuni infected mice.
Discussion
The physiological colonization resistance protecting the vertebrate host from unwanted pathogenic coloniza-
tion and infection provides us promising opportunities to identify distinct molecules and gut bacterial popu-
lations as potential novel options for the prevention and treatment of campylobacterisis and its post-infectious 
sequelae. We are currently, however, still at the beginning of understanding the underlying mechanisms. In our 
actual antibiotics-independent intervention study applying a murine high dose C. jejuni infection model, we 
were able to show that murine FMT treatment of secondary abiotic mice harboring very high pathogenic loads of 
approximately 109 viable bacteria per g intestinal luminal sample lowered gastrointestinal C. jejuni loads up to 7.5 
orders of magnitude within two weeks post-intervention. This pronounced pathogen-lowering effect is even more 
intriguing when considering the low infectious doses of a few hundred bacterial cells needed to induce campylo-
bacteriosis in humans5. Besides the substantial pathogen-lowering effect, murine FMT did also affect the murine 
C. jejuni carrier rates given that 12.5% of high-dose infected mice had even completely expelled the pathogen 
from their GIT. Remarkably, FMT could effectively reverse C. jejuni induced colonic epithelial apoptosis, and 
enhance proliferative and regenerative cell responses in the large intestines thereby counteracting pathogenic cell 
damage. Furthermore, FMT dampened both, innate and adaptive immune cell responses in the large intestines 
upon C. jejuni infection that was accompanied by less secretion of nitric oxide exerting oxidative stress to the 
intestinal epithelia26,27. In support, we were able to show very recently that murine FMT could decrease intestinal 
loads of the Gram-negative opportunistic pathogen Pseudomonas aeruginosa in murine carriers28. The immune 
cell function restoring properties of murine FMT in secondary abiotic mice was convincingly shown by Ekmekciu 
and coworkers previously. Whereas gut microbiota depletion by broad-spectrum antibiotic treatment resulted in 
profound changes of the immune cell repertoire in local intestinal and systemic compartments, reintroduction of 
the complex murine gut microbiota by peroral FMT could reverse the collateral damages of antibiotic treatment16.
A key question is whether the entire complex gut microbiota, defined bacterial species alone or in combi-
nation, and/or distinct molecules shaping a (for the pathogen) hostile intraluminal milieu within the GIT are 
needed to expel the pathogen from already taken ecological niches. Our recent study revealed that application of a 
single Lactobacillus johnsonii strain that had been isolated from a healthy conventional C57BL/6j mouse resulted 
in ameliorated intestinal, extra-intestinal and even systemic immune responses upon high-dose C. jejuni infection 
of secondary abiotic mice in a time-of-treatment dependent fashion29, but without having a pathogen-lowering 
effect. Ekmekciu et al. further addressed the capabilities of defined Gram-positive and Gram-negative intestinal 
Figure 3. Fecal commensal microbiota composition following fecal microbiota transplantation in C. jejuni 
infected secondary abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 1 by gavage. 
Starting a week later, infected mice were subjected to peroral fecal microbiota transplantation (FMT) from 
murine donors (open circles; n = 16) on three consecutive days or received vehicle (mock; closed circles; 
n = 13). On day 21 post-infection (i.e., 14 days post FMT), the fecal commensal microbiota composition was 
surveyed by culture-independent 16S rRNA methods quantitating the main bacterial groups and species 
including enterobacteria (EB), enterococci (EC), lactobacilli (LB), bifidobacteria (BB), Bacteroides/Prevotella 
(BP) species, Clostridium coccoides group (CC), Clostridium leptum group (CL) and Mouse Intestinal Bacteroides 
(MIB) and expressed as gene numbers per ng DNA. Medians and significance levels (p-values; **p < 0.01; 
***p < 0.001) determined by the Mann-Whitney U test are given. Data were pooled from three independent 
experiments.
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commensals such as Lactobacillus johnsonii and Escherichia coli, respectively, to restore cellular immune func-
tions as compared to complex microbiota in mice that had been subjected to broad-spectrum antibiotic treat-
ment with subsequent immune-suppressive sequelae30. In fact, FMT appeared to be most potent to reverse 
antibiotics-induced immune dysfunction, whereas respective commensal species could effectively restore individ-
ual functions of both, intestinal and systemic immunity. Furthermore, recolonization of secondary abiotic mice 
with the probiotic formulation VSL#3 consisting of eight bacterial strains (i.e., four different Lactobacillus species, 
three Bifidobacterium species and Streptococcus thermophilus), has been shown to reverse antibiotics-induced 
immune cellular dysfunction and to provide anti-inflammatory responses in intestinal mucosal and systemic 
compartments31. Notably, probiotic VSL#3 treatment of C. jejuni infected secondary abiotic mice could alleviate 
intestinal and extra-intestinal including systemic sequelae of infection32.
Nevertheless, it appears to be rather a search for the needle in the hay-stack when trying to identify effective 
pathogen-lowering and immune-modulatory (probiotic) bacterial strains. It is rather more likely, that literally, the 
orchestrated interplay of commensals with the immune system as the conductor constitutes the most promising 
approach to tackle intestinal pathogenic colonization/infection of vertebrates.
From disease-preventive strategies of human campylobacteriosis, however, it is of even more importance to 
lower the intestinal C. jejuni loads in poultry and other livestock animals for subsequent risk reduction of path-
ogenic transmission to human via the food chain. In support, both, prophylactic and therapeutic application of 
a commercial bacterial formulation (Aviguard®) has been successfully shown to compete with intestinal coloni-
zation and expansion, respectively, of chicken with unwanted bacteria such as Clostridium perfringens33,34 and 
Salmonella typhimurium35 additionally resulting in less distinct intestinal inflammatory sequelae of colonization/
infection. We are currently evaluating potential intestinal pathogenic burden lowering and anti-inflammatory 
effects of prophylactic and therapeutic application in high-dose C. jejuni infected mice.
in conclusion. Our intervention study provides strong evidence that active modulation of the microbiota 
composition by murine FMT might be considered an effective measure to lower even high intestinal C. jejuni 
loads and dampen pathogen-induced inflammatory immune responses in colonized/infected vertebrates includ-
ing farm animals. Subsequent application-oriented efforts to develop pharmaceutical probiotic formulations 
that might even replace FMT in clinical practice36 would provide novel options for a safe, easy-to-handle and 
(hopefully) cost-efficient treatment of C. jejuni infections in humans. From the prophylactic perspective, efficient 
reduction of C. jejuni colonization in farm animals would minimize the risk of pathogenic transmission via the 
food chain, of human infection and of post-infectious sequelae.
Figure 4. Apoptotic and proliferating colonic epithelial cell responses upon fecal microbiota transplantation 
of C. jejuni infected secondary abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 
1 by gavage. Starting a week later, infected mice were subjected to peroral fecal microbiota transplantation 
(FMT) from murine donors (open circles) on three consecutive days or received vehicle (mock; closed circles). 
On day 21 post-infection (i.e., 14 days post FMT), the average numbers of (A) apoptotic (caspase3, Casp3+) 
and (B) proliferating (Ki67+) colonic epithelial cells were determined from six high power fields (HPF, 
400 × magnification) per mouse in immunohistochemically stained large intestinal paraffin sections. Naive 
secondary abiotic mice served as uninfected and untreated controls (open diamonds). Medians, numbers of 
analyzed animals (in parentheses) and significance levels (p-values) determined by the Mann-Whitney U test 
are given. Data were pooled from three independent experiments.
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Materials and Methods
ethical statement. Mouse experiments were conducted in accordance with the European Guidelines for 
animal welfare (2010/63/EU) after approval by the commission for animal experiments headed by the “Landesamt 
für Gesundheit und Soziales” (LaGeSo, Berlin, registration numbers G0097/12 and G0039/15. One a day clinical 
conditions of mice were monitored.
Figure 5. Colonic immune cells responses upon fecal microbiota transplantation of C. jejuni infected 
secondary abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 1 by gavage. Starting 
a week later, infected mice were subjected to peroral fecal microbiota transplantation (FMT) from murine 
donors (open circles) on three consecutive days or received vehicle (mock; closed circles). On day 21 post-
infection (i.e., 14 days post FMT), the average numbers of (A) macrophages and monocytes (F4/80+), (B) T 
lymphocytes (CD3+), (C) regulatory T cells (FOXP3+), and (D) B lymphocytes (B220+) in the large intestinal 
mucosa and lamina propria were determined from six high power fields (HPF, 400 x magnification) per mouse 
in immunohistochemically stained large intestinal paraffin sections. Naive secondary abiotic mice served as 
uninfected and untreated controls (open diamonds). Medians, numbers of analyzed animals (in parentheses) 
and significance levels (p-values) determined by the Mann-Whitney U test are given. Data were pooled from 
three independent experiments.
7Scientific RepoRtS |         (2019) 9:19797  | https://doi.org/10.1038/s41598-019-56442-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Generation of secondary abiotic mice. Conventional female and male C57BL/6j mice were bred 
and reared under specific pathogen free (SPF) conditions in the same unit of the Forschungseinrichtungen 
für Experimentelle Medizin (FEM, Charité - University Medicine Berlin). In order to counteract physiologi-
cal colonization resistance, secondary abiotic mice with a depleted gut microbiota were generated as described 
previously17,26. In brief, upon weaning 3-week old mice were placed into autoclaved cages and subjected to 
broad-spectrum antibiotic treatment for 8 weeks (ampicillin plus sulbactam (1 g/L; Ratiopharm, Germany), 
vancomycin (500 mg/L; Cell Pharm, Germany), ciprofloxacin (200 mg/L; Bayer Vital, Germany), imipenem 
(250 mg/L; MSD, Germany) and metronidazole (1 g/L; Fresenius, Germany)) added to autoclaved tap water. To 
control the intestinal colonization status and absence of cultivable bacteria in the murine intestinal tract, indi-
vidual fecal samples were derived once a week as well as immediately before the first C. jejuni infection and incu-
bated in thioglycolate broths (Oxoid) for one week at 37 °C. Bacterial growth was monitored daily by turbidity 
assessment. Aliquots from turbid broths as well as from broths remaining clear after one week of incubation were 
cultivated on solid media under aerobic, microaerobic and obligate anaerobic conditions and grown bacteria 
identified microscopically and biochemically as described26. Virtual absence of fastidious and uncultivable bac-
teria in intestinal tract of secondary abiotic mice has been confirmed in our previous study by quantitative 16S 
rRNA based PCR analyses showing that bacterial gene numbers in fecal samples following quintuple antibiotic 
treatment were comparable to those detected in autoclaved food pellets16. Three days before start of the infection 
experiments the antibiotic cocktail was replaced by autoclaved tap water (ad libitum).
C. jejuni infection and colonization properties. At days 0 and 1, sex and age matched secondary abiotic 
mice were perorally infected with 109 colony forming units (CFU) of the C. jejuni 81–176 strain by gavage (in a 
total volume of 0.3 mL phosphate buffered saline (PBS, Gibco, Life Technologies, UK)). Animals remained in a 
sterile environment (with autoclaved food and drinking water or sterile antibiotic cocktail) and handled under 
strictly aseptic conditions to avoid contaminations.
C. jejuni loads were quantitatively assessed in fecal samples over time post-infection and upon necropsy (i.e., 
at day 21 p.i.) in luminal samples derived from the stomach, duodenum, ileum, and colon by culture as reported 
earlier17,37. The detection limit of viable pathogens was 100 CFU per g.
fecal microbiota transplantation. On days 7, 8 and 9 p.i., mice were subjected to peroral FMT from 
murine donors on three consecutive days. Fresh murine fecal samples were collected from 10 age and sex matched 
SPF control mice, pooled, dissolved in 10 mL sterile PBS and the supernatant taken as murine donor suspension. 
Aliquots from each murine fecal donor solutions were collected for quantitative molecular analyses of main intes-
tinal bacterial communities as reported previously17,26,38 (Supplementary Information).
Figure 6. Colonic nitric oxide secretion upon fecal microbiota transplantation of C. jejuni infected secondary 
abiotic mice. Secondary abiotic mice were infected with C. jejuni on days 0 and 1 by gavage. Starting a week 
later, infected mice were subjected to peroral fecal microbiota transplantation (FMT) from murine donors 
(open circles) on three consecutive days or received vehicle (mock; closed circles). On day 21 post-infection 
(i.e., 14 days post FMT), nitric oxide concentrations were measured in supernatants of colonic ex vivo biopsies. 
Naive secondary abiotic mice served as uninfected and untreated controls (open diamonds). Medians, numbers 
of analyzed animals (in parentheses) and significance levels (p-values) determined by the Mann-Whitney U test 
are given. Data were pooled from three independent experiments.
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Molecular analysis of gut microbiota composition. DNA was extracted from fecal and colonic lumi-
nal samples as well as from fecal docor suspensions as described previously26,39. In brief, DNA was quantified by 
using Quant-iT PicoGreen reagent (Invitrogen, UK) and adjusted to 1 ng per µL. Then, the main bacterial species 
and groups abundant in the murine gut microbiota including enterobacteria, enterococci, lactobacilli, bifidobac-
teria, Bacteroides/Prevotella spp., Clostridium coccoides group, Clostridium leptum group, and Mouse Intestinal 
Bacteroides were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) with species-, genera- 
or group-specific 16S rRNA gene primers (Tib MolBiol, Germany) as stated elsewhere17,38,40 and expressed as 
numbers of 16S rRNA gene copies per ng DNA.
Sampling procedures. Mice were sacrificed at day 21 p.i. (i.e., 14 days post-FMT) by isofluran inhalation 
(Abbott, Germany). Luminal samples were derived from distinct parts of the GIT (i.e., from stomach, duodenum 
ileum, and colon) and ex vivo biopsies from the large intestines were taken under sterile conditions. From each 
mouse colonic samples were collected in parallel for microbiological, immunohistopathological and immuno-
logical analyses.
Immunohistochemistry. Colonic ex vivo biopsies were immediately fixed in 5% formalin, embedded in 
paraffin and subjected to in situ immunohistochemical analyses as stated elsewhere38,41–43. In brief, apoptotic 
epithelial cells, proliferating epithelial cells, macrophages/monocytes, T lymphocytes, regulatory T cells, and B 
lymphocytes were quantitated in paraffin sections (5 μm) that had been stained with primary antibodies against 
cleaved caspase 3 (Asp175, Cell Signaling, Beverly, MA, USA, 1:200), Ki67 (TEC3, Dako, Denmark, 1:100), F4/80 
(# 14–4801, clone BM8, eBioscience, San Diego, CA, USA, 1:50), CD3 (#N1580, Dako, 1:10), FOXP3 (FJK-16s, 
eBioscience, 1:100), and B220 (No. 14-0452-81, eBioscience; 1:200), respectively. Positively stained cells were 
counted by a blinded independent investigator (light microscopy, magnification 100 x and 400 x), and the aver-
age number of respective positively stained cells for each mouse determined within at least six high power fields 
(HPF, 0.287 mm2, 400 x magnification).
nitric oxide measurement. Colonic ex vivo biopsies were cut longitudinally, washed in PBS, and strips of 
approximately 1 cm2 tissues were placed in 24-flat-bottom well culture plates (Nunc, Germany) containing 500 
μL serum-free RPMI 1640 medium (Gibco, life technologies, UK) supplemented with penicillin (100 U/mL) and 
streptomycin (100 µg/mL; PAA Laboratories, Germany). After 18 h at 37 °C, culture supernatants were subjected 
to nitric oxide concentration measurements applying the Griess reaction as stated elsewhere26,27.
Statistical analysis. Medians and levels of significance were determined using Mann-Whitney test 
(GraphPad Prism v7, USA) as indicated. Two-sided probability (p) values ≤ 0.05 were considered significant. 
Experiments were reproduced twice.
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